Skip to main content
$39.41 -$0.51 (-1.3%)

02:58 PM EDT on 08/14/20

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Current Price $39.41 Mkt Cap $6.3B
Open $39.85 P/E Ratio 0.00
Prev. Close $39.91 Div. (Yield) $0.00 (0.0%)
Daily Range $39.27 - $39.99 Volume 631,904
52-Wk Range $23.77 - $58.72 Avg. Daily Vol. 2,227,605

Caps

How do you think NASDAQ:ACAD will perform against the market?

Add Stock to CAPS Watchlist

All Players

286 Outperform
73 Underperform
 

All-Star Players

39 Outperform
19 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACAD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MarkBiotech (< 20)
Submitted April 05, 2017

Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More

constructive (97.58)
Submitted March 03, 2017

This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More

Recent Community Commentary

Read the most recent pitches from players about ACAD.

Recs

0
Member Avatar LifeScientist (< 20) Submitted: 7/2/2020 3:08:37 PM : Outperform Start Price: $52.08 NASDAQ:ACAD Score: -31.26

The principal pipieline drug Nuplazid seeking fda approval is already market for Parkinson’s patients. Wow, my own Mom could benefit! ....we’ve been seeking a drug that would help her hallucinations w dementia. sNDA on dementia now....hope it works and is covered by insurance!

Recs

0
Member Avatar wrciii (73.01) Submitted: 6/5/2020 6:30:37 AM : Outperform Start Price: $46.55 NASDAQ:ACAD Score: -20.96

Salveen R + Haen

Recs

0
Member Avatar NHWeston102 (78.94) Submitted: 5/2/2020 2:10:25 PM : Outperform Start Price: $47.37 NASDAQ:ACAD Score: -34.37

Leading dementia treatment candidates.

Leaderboard

Find the members with the highest scoring picks in ACAD.

Score Leader

jamrod02

jamrod02 (58.97) Score: +4,870.36

The Score Leader is the player with the highest score across all their picks in ACAD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jamrod02 58.97 12/20/2010 Outperform 5Y $0.77 +5,040.28% +169.91% +4,870.36 0 Comment
noobtery < 20 10/28/2010 Outperform 5Y $0.83 +4,668.07% +183.04% +4,485.04 0 Comment
Hornet41 56.19 12/22/2010 Outperform 5Y $0.90 +4,296.73% +168.11% +4,128.63 0 Comment
Ruckwerts 46.10 12/1/2011 Outperform 3Y $0.93 +4,155.38% +169.63% +3,985.74 0 Comment
dsherid2 < 20 11/30/2011 Outperform 1Y $1.03 +3,742.61% +170.78% +3,571.82 0 Comment
Smog79 21.25 8/12/2010 Outperform 3W $1.04 +3,705.29% +209.75% +3,495.54 0 Comment
drmanand 55.98 7/14/2010 Outperform 1Y $1.11 +3,465.96% +207.77% +3,258.19 1 Comment
smallandmidcap 93.92 8/10/2010 Outperform 5Y $1.13 +3,402.21% +200.29% +3,201.92 0 Comment
dmkj50 < 20 10/27/2011 Outperform 5Y $1.17 +3,282.19% +162.97% +3,119.22 0 Comment
tappo3833 91.99 1/3/2011 Outperform 1Y $1.19 +3,225.63% +165.50% +3,060.13 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACAD.